Equetro

Equetro is a brand name of carbamazepine, approved by the FDA in the following formulation(s):

EQUETRO (carbamazepine - capsule, extended release; oral)

• 
  Manufacturer: VALIDUS PHARMS INC
  
  Approval date: December 10, 2004
  
  Strength(s): 100MG, 200MG, 300MG ^[RLD]

Has a generic version of Equetro been approved?

No. There is currently no therapeutically equivalent version of Equetro available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Equetro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
  Patent 5,326,570
  Issued: July 5, 1994
  Inventor(s): Rudnic; Edward M. & Belendiuk; George W.
  Assignee(s): Pharmavene, Inc.
  The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
  
  Patent expiration dates:
  
  
  • July 23, 2011
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
    ✓ 
    Drug product
  
  



• 
  Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
  Patent 5,912,013
  Issued: June 15, 1999
  Inventor(s): Rudnic; Edward M. & Belendiuk; George W. & McCarty; John & Wassink; Sandra & Couch; Richard A.
  Assignee(s): Shire Laboratories, Inc.
  The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
  
  Patent expiration dates:
  
  
  • June 15, 2016
    
    ✓ 
    Drug product
  
  



• 
  Methods for the treatment of bipolar disorder using carbamazepine
  Patent 6,977,253
  Issued: December 20, 2005
  Inventor(s): Kalali; Amir H. & Tulloch; Simon J.
  Assignee(s): Shire Pharmaceutical Development Inc.
  Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.
  
  Patent expiration dates:
  
  
  • May 19, 2024
    
    ✓ 
    Patent use: THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
  
  

See also...

• Equetro Consumer Information (Drugs.com)
• Equetro Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Equetro Consumer Information (Cerner Multum)
• Equetro Advanced Consumer Information (Micromedex)
• Carbamazepine Consumer Information (Drugs.com)
• Carbamazepine Consumer Information (Wolters Kluwer)
• Carbamazepine Chewable Tablets Consumer Information (Wolters Kluwer)
• Carbamazepine Suspension Consumer Information (Wolters Kluwer)
• Carbamazepine Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Carbamazepine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Carbamazepine Consumer Information (Cerner Multum)
• Carbamazepine Advanced Consumer Information (Micromedex)
• Carbamazepine AHFS DI Monographs (ASHP)